山 西 制 药 股 份 有 限 公 司 财 务 报 表 造 假及 其 治 理 措 施摘 要近年来，许多企业一味追求上市，不考虑自身财务能力以及承受风险的能力 在IPO 上市未通过后多数破产或者转投，其中上市公司也由于产业发展超负荷支撑，造成银行等金融机构大量的坏死账以及企业不良资产的产生，企业负债繁重，最后只有政府出面买单。因此，研究上市公司财务造假问题具有重要的理论意义和现实意义。本文首先对财务造假相关理论做了梳理归纳，然后对山西振东制药股份有限公司财务造假进行了介绍，接着对山西振东制药股份有限公司财务造假的案例进行了原因分析，最后结合理论和的情况对我国加强财务造假的治理提出了对策建议。关键词：财务造假；治理；山西振东制药股份有限公司IAbstractDevotion to public in recent years, many enterprises, regardless of their financial ability and the ability to take risks After IPO failed most bankruptcy or switch to, listed companies are also due to the overload support of industrial development, causing bank account, and a large number of financial institutions, such as necrosis of non-performing assets of the enterprise, enterprise debt burden, only the government to pay. Therefore, the research of the listed company financial fraud problems has important theoretical significance and practical significance. At first, this paper made a comb, the financial fraud related theory and then to Shanxi cooperates pharmaceutical co., LTD., financial fraud are introduced, and then to Shanxi cooperates pharmaceutical co., LTD., the reason of financial fraud case analysis, finally combining with the theory and the situation of our country to strengthen the management of financial fraud countermeasures and Suggestions are put forward.Key words: financial fraud;Management;Shanxi cooperates pharmaceutical co., LTDII目 录一、 引言...............................................................................................................
